



Name of the issue:

NEOCHEM BIO SOLUTIONS LIMITED

- 1 **Type of issue (IPO/ FPO)** Initial Public Offer (IPO) on SME Platform
- 2 **Issue size (Rs Lakhs)** 4497.02
- 3 **Grade of issue alongwith name of the rating agency** Not Applicable
- 4 **Subscription level (number of times)*** 11.20
**Source: Basis of allotment - After removing technical rejections, duplicate and multiple bids*
- 5 **QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges**

Particulars	% holding
(i) allotment in the issue	0.64%
(ii) at the end of the 1st Quarter immediately after the listing of the issue, i.e., March, 2026	-
(iii) at the end of FY 2025- 26	-
(iv) at the end of FY 2026-27	-
(v) at the end of FY 2028-29	-

6 **Financials of the issuer**

(Rs. in Lakhs)

Parameters	FY 2025-26	FY 2026-27	FY 2028-29
Income from operations	11,339.35	Not Available	Not Available
Net Profit for the period	1,202.66	Not Available	Not Available
Paid-up equity share capital	1,712.08	Not Available	Not Available
Reserves excluding revaluation reserves	6,172.40	Not Available	Not Available

7 **Trading status in the scrip of the issuer**

Particulars	Status
(i) at the end of FY 2025- 26	Trading
(ii) at the end of FY 2026-27	Not Available
(iii) at the end of FY 2027-28	Not Available



8 **Change, if any, in directors of issuer from the disclosures in the offer document**

Particulars	Name of the Directors	Appointment/ Cessation/Demise
(i) at the end of FY 2025- 26	-	-
(ii) at the end of FY 2026-27	Not Available	Not Available
(iii) at the end of FY 2027-28	Not Available	Not Available

9 **Status of implementation of project/ commencement of commercial production**

(i) As disclosed in the offer document

(₹ in Lakh)

Objects of the Issue	Amount to be funded from Net Proceeds	Amount to be deployed from the Net Proceeds in FY 2025-26
	Not Available	Not Available
	Not Available	Not Available
Total	Not Available	Not Available

(ii) Actual utilization

-

iii) Reasons for delay in implementation, if any

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document

(₹ in Lakh)

Objects of the Issue	Amount to be funded from Net Proceeds	Amount to be deployed from the Net Proceeds in FY 2026-27	Amount to be deployed from the Net Proceeds in FY 2027-28
Funding capital expenditure towards acquisition of six pre-owned aircraft on long term dry lease basis	2,390.00	990.00	1,400.00
Repayment/prepayment, in full or part, certain	1000.00	1000.00	0.00
General Corporate Purposes	643.55	643.55	0.00
Total	4,033.55	2,633.55	1,400.00

(ii) Actual utilization

(₹ in Lakh)

Objects of the Issue	Amount utilized till March 31, 2026
Utilization towards long-term working capital requirements of	Not Available
For General Corporate Purposes	Not Available
Total	0.00

(Source: Information filed with stock exchange in terms of SEBI LODR Regulations)

iii) Reasons for deviations, if any

Not Available

11 Comments of monitoring agency, if applicable

(a) Comments on use of funds	Not Applicable
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds (To be submitted till the time the issue proceeds have been fully utilised)	

12 Price- related data

Issue price (Rs): 98.00 per Equity Share

Price parameters	At close of listing day i.e. December 09, 2025	At close of 30th calendar day from listing day (January 09, 2026)	At close of 90th calendar day from listing day (March 09, 2026)	As at the end of FY 2025-26		
				Closing price	High	Low
Market Price	111.80	80.92	Not Available	63.25	65.90	63.00
Index (of the Designated Stock Exchange): NSE Emerge	13,044.15	13044.15	12,197.50	11,025.80	11,391.45	11,015.55
Sectoral Index (mention the index that has been considered and reasons for considering the same)	Not comparable to any of the available sectoral indices					

In case 30th/90th/180th day is not a trading day, closing price on NSE Emerge of the next trading day has been considered.



13 Basis for Issue Price and Comparison with Peer Group & Industry Average

Accounting ratio	Name of Company	Consolidated/ Standalone	As disclosed in the offer document ⁽¹⁾	At the end of FY 2025-26	At the end of FY 2026-27	At the end of FY 2027-28
EPS	Issuer	Consolidated	4.52	8.71		
	Peer Group:		NOT APPLICABLE			
	Industry Avg:		NOT APPLICABLE			
PE	Issuer	Consolidated	18.10	7.26		
	Peer Group:		NOT APPLICABLE			
	Industry Avg:		NOT APPLICABLE			
RoNW	Issuer	Consolidated	21.10%	24.40%		
	Peer Group:		NOT APPLICABLE			
	Industry Avg:		NOT APPLICABLE			
NAV per share based on balance sheet	Issuer	Consolidated	25.72	46.05		
	Peer Group:		NOT APPLICABLE			
	Industry Avg:		NOT APPLICABLE			

⁽¹⁾ Sourced from the Prospectus dated December 04, 2025

14 Any other material information

Nil